Kymera Therapeutics (NASDAQ:KYMR) Issues Quarterly Earnings Results

Kymera Therapeutics (NASDAQ:KYMR - Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.82) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.83) by $0.01, Briefing.com reports. Kymera Therapeutics had a negative net margin of 178.27% and a negative return on equity of 28.88%. The company had revenue of $3.74 million for the quarter, compared to the consensus estimate of $10.34 million. During the same period in the previous year, the firm posted ($0.90) EPS. Kymera Therapeutics's revenue for the quarter was down 20.9% compared to the same quarter last year.

Kymera Therapeutics Price Performance

Shares of NASDAQ:KYMR traded up $0.30 during trading hours on Friday, hitting $46.47. 432,609 shares of the company's stock traded hands, compared to its average volume of 597,398. The firm has a market capitalization of $2.87 billion, a P/E ratio of -19.20 and a beta of 2.21. The business has a fifty day moving average price of $47.04 and a 200-day moving average price of $40.65. Kymera Therapeutics has a 1 year low of $9.60 and a 1 year high of $53.27.

Insider Transactions at Kymera Therapeutics

In related news, Director Jeffrey W. Albers sold 5,000 shares of the business's stock in a transaction on Monday, August 26th. The stock was sold at an average price of $49.10, for a total transaction of $245,500.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. In related news, Director Jeffrey W. Albers sold 5,000 shares of Kymera Therapeutics stock in a transaction dated Monday, August 26th. The shares were sold at an average price of $49.10, for a total transaction of $245,500.00. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Pamela Esposito sold 13,500 shares of the company's stock in a transaction dated Tuesday, September 17th. The stock was sold at an average price of $48.28, for a total transaction of $651,780.00. The disclosure for this sale can be found here. Company insiders own 15.82% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have recently issued reports on the company. Morgan Stanley lifted their target price on Kymera Therapeutics from $34.00 to $45.00 and gave the stock an "equal weight" rating in a report on Wednesday, August 14th. Truist Financial reaffirmed a "buy" rating and set a $53.00 price objective (down from $54.00) on shares of Kymera Therapeutics in a report on Friday. Guggenheim raised their target price on shares of Kymera Therapeutics from $45.00 to $52.00 and gave the company a "buy" rating in a report on Friday. Wells Fargo & Company upped their price target on shares of Kymera Therapeutics from $30.00 to $38.00 and gave the company an "equal weight" rating in a research note on Monday, August 12th. Finally, Leerink Partnrs raised shares of Kymera Therapeutics to a "strong-buy" rating in a research note on Monday, September 9th. Four investment analysts have rated the stock with a hold rating, nine have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $49.15.

About Kymera Therapeutics

Kymera Therapeutics, Inc, a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body's own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase II clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors.